RTW Venture Fund Limited March Factsheet & First Quarter Letter (2631X)
24 Abril 2023 - 10:39AM
UK Regulatory
TIDMRTW
RNS Number : 2631X
RTW Venture Fund Limited
24 April 2023
LEI: 549300Q7EXQQH6KF7Z84
24 April 2023
RTW Venture Fund Limited
March Factsheet & First Quarter Letter
-2.7% NAV Return for the Quarter Ended 31 March 2023
RTW Venture Fund Limited (the "Company"), the London Stock
Exchange Premium Listed investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors is pleased to
announce that the March Factsheet and First Quarter 2023 Letter are
available on the Company's website.
Developments in the quarter:
-- The Russell 2000 Biotech Index (-8.0%) and the Nasdaq Biotech
Index (-2.1%) fell over the quarter despite significant M&A in
the sector.
-- Cincor was acquired by AstraZeneca for a total deal value of
$1.8bn, a 206% premium to the prior closing value.
-- Orchestra BioMed merged with RTW's Health Sciences
Acquisitions Corporation and started trading on Nasdaq.
-- Mineralys went public through an upsized IPO and traded well
on debut.
-- The Company co-led private financing rounds in two cell
therapy companies: Orciell Therapeutics and Cargo Therapeutics.
-- Milestone announced a $125m strategic financing deal with
RTW-managed funds include the Company
-- Avidity announced that discussions with the FDA were ongoing
regarding the partial clinical hold of it Phase 1/2 clinical trial
for AOC1001.
-- After the quarter end, Prometheus Biosciences, the Company's
largest position was acquired by Merck for $10.8bn, a 75% premium
to the prior closing value.
For Further Information:
RTW Investments, LP +44 (0)20 7959 6361
Woody Stileman, Managing Director
Krisha McCune, Director, Client Service
Buchanan +44 (0)20 7466 5107
Charles Ryland
Henry Wilson
George Beale
Numis +44 (0)20 7260 1000
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities +44 (0) 20 7628 1000
Edward Peel
Kieran Millar
Elysium Fund Management Limited +44 (0) 14 8181 0100
Joanna Duquemin Nicolle, Chief Executive Officer
Sadie Morrison, Managing Director
Morgan Stanley Fund Services USA LLC +1 (914) 225 8885
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment
fund focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund invests in companies developing
next-generation therapies and technologies that can significantly
improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUQGCUPWGWC
(END) Dow Jones Newswires
April 24, 2023 09:39 ET (13:39 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Rtw Biotech Opportunities (LSE:RTWG)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
